Semaglutide Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous (weekly injection); Oral tablet available (Rybelsus) Frequency: Once weekly (SC); Once daily (oral) Dose Range: SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day Cycle Length: 16–20+ weeks; ongoing for weight management Timing: Same day each week at any time, with or without meals (SC); empty stomach 30 min before food (oral)
Reconstitution
Vial Size: 5mg Water Volume: 2mL Concentration: 2.5mg/mL
Titration Schedule
Weeks 1–4: 0.25 mg (10 units) Weeks 5–8: 0.5 mg (20 units) Weeks 9–12: 1.0 mg (40 units) Weeks 13–16: 1.7 mg (68 units) Weeks 17+ (maintenance): 2.4 mg (96 units)
Timeline & Pharmacokinetics
Onset: 24–72 hours (appetite suppression) Peak Plasma: 1–3 days post-injection Half-Life: ~168 hours (~7 days) Steady State: 4–5 weeks of weekly dosing Time to Results: 4–8 weeks for appetite changes; 12–16 weeks for significant weight loss Washout: 5–7 weeks (5 half-lives)
Storage
Lyophilized: −20 °C (−4 °F), dry, protected from light Reconstituted: 2–8 °C (35.6–46.4 °F); use within 28 days Shelf Life: 28 days
Injection Sites
Abdomen (preferred for consistent absorption), Thighs, Upper arms
Safety & Contraindications
Safety: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
Contraindications: Personal or family history of medullary thyroid carcinoma; Multiple endocrine neoplasia syndrome type 2 (MEN2); History of pancreatitis
Related Products
Semaglutide 10mg
10mg
Related Research News
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research.
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.